Takeda has announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. These data were presented on June 9, 2022, at the 8th Northern European Conference on Travel Medicine (NECTM8), with plans to feature the results at additional upcoming conferences.

For more details, check out the full story on the link below:     

Takeda Dengue Vaccine TAK-003 Provides Continued Protection Against Dengue Fever Through 4.5 Years In Trial

Leave a Reply

Your email address will not be published. Required fields are marked *